This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Melnick, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Melnick, J. L.

 Previous Article  |  Next Article 

Clinical Microbiology Reviews, 07 1996, 293-300, Vol 9, No. 3
Copyright © 1996 by the American Society for Microbiology. All rights reserved.

Current status of poliovirus infections

JL Melnick
Division of Molecular Virology, Baylor College of Medicine, Houston, Texas 77030, USA.

Two scientists who played leading roles in the conquest of poliomyelitis died recently. In 1954, Jonas Salk provided the first licensed polio vaccine, the formalin (and heat)-inactivated virus. Albert Sabin gave us the attenuated live virus vaccine, which was licensed in 1962. This paper takes the reader through the history of the disease, including its pathogenesis, epidemiology, vaccines, and future directions. The emphasis is on vaccines, for it seems that with proper vaccination the number of new cases is falling dramatically. It is hoped that by the year 2000, we will accomplish the goal of the World Health Organization of "a world without polio." Then, because there is no animal reservoir, we can seriously discuss when and how to eliminate the need for vaccination and ultimately destroy our stocks of poliovirus.


This article has been cited by other articles:

  • Laassri, M., Dragunsky, E., Enterline, J., Eremeeva, T., Ivanova, O., Lottenbach, K., Belshe, R., Chumakov, K. (2005). Genomic Analysis of Vaccine-Derived Poliovirus Strains in Stool Specimens by Combination of Full-Length PCR and Oligonucleotide Microarray Hybridization. J. Clin. Microbiol. 43: 2886-2894 [Abstract] [Full Text]  
  • Salvati, A. L., De Dominicis, A., Tait, S., Canitano, A., Lahm, A., Fiore, L. (2004). Mechanism of Action at the Molecular Level of the Antiviral Drug 3(2H)-Isoflavene against Type 2 Poliovirus. Antimicrob. Agents Chemother. 48: 2233-2243 [Abstract] [Full Text]  
  • El Bassioni, L., Barakat, I., Nasr, E., de Gourville, E. M., Hovi, T., Blomqvist, S., Burns, C., Stenvik, M., Gary, H., Kew, O. M., Pallansch, M. A., Wahdan, M. H. (2003). Prolonged Detection of Indigenous Wild Polioviruses in Sewage from Communities in Egypt. Am J Epidemiol 158: 807-815 [Abstract] [Full Text]  
  • Girn, J., Kavoosi, M., Chantler, J. (2002). Enhancement of coxsackievirus B3 infection by antibody to a different coxsackievirus strain. J. Gen. Virol. 83: 351-358 [Abstract] [Full Text]  
  • Muir, P., Kammerer, U., Korn, K., Mulders, M. N., Poyry, T., Weissbrich, B., Kandolf, R., Cleator, G. M., van Loon, A. M. (1998). Molecular Typing of Enteroviruses: Current Status and Future Requirements. Clin. Microbiol. Rev. 11: 202-227 [Abstract] [Full Text]